Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 300 | 65 | 224 |
| Samples | 286 | 64 | 214 |
| Peptides | 211 | 47 | 166 |
Function
TAF6L · TATA-box binding protein associated factor 6 like
Initiation of transcription by RNA polymerase II requires the activities of more than 70 polypeptides. The protein that coordinates these activities is transcription factor IID (TFIID), which binds to the core promoter to position the polymerase properly, serves as the scaffold for assembly of the remainder of the transcription complex, and acts as a channel for regulatory signals. TFIID is composed of the TATA-binding protein (TBP) and a group of evolutionarily conserved proteins known as TBP-associated factors or TAFs. TAFs may participate in basal transcription, serve as coactivators, function in promoter recognition or modify general transcription factors (GTFs) to facilitate complex assembly and transcription initiation. This gene encodes a protein that is a component of the PCAF histone acetylase complex and structurally similar to one of the histone-like TAFs, TAF6. The PCAF histone acetylase complex, which is composed of more than 20 polypeptides some of which are TAFs, is required for myogenic transcription and differentiation. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000294168 | Q9Y6J9 | 300 | 211 |
Gene Properties
Recurrent Mutations
All 211 amino-acid changes on canonical ENST00000294168 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in TAF6L · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in TAF6L – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Endometrial Carcinoma | 0/42 0% | 12/612 2% |
| Cervical Carcinoma | 2/35 6% | 6/422 1% |
| Mesothelioma | 3/62 5% | 0/165 0% |
| Bladder Carcinoma | 2/58 3% | 11/956 1% |
| Melanoma | 0/210 0% | 24/1899 1% |
| Chondrosarcoma | 1/14 7% | 0/75 0% |
| Colorectal Carcinoma | 10/143 7% | 28/3239 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Other Solid Cancers | 2/94 2% | 15/1515 1% |
| Gastric Carcinoma | 1/74 1% | 17/1809 1% |
| Neuroendocrine Tumour | 5/154 3% | 2/577 0% |
| Ewings Sarcoma | 3/63 5% | 0/262 0% |
| Esophageal Squamous Cell Carcinoma | 3/51 6% | 20/2550 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Non-Small Cell Lung Carcinoma | 4/304 1% | 7/1390 0% |
| Esophageal Carcinoma | 1/23 4% | 4/769 1% |
| Plasma Cell Myeloma | 2/44 5% | 0/305 0% |
| Glioma | 0/52 0% | 12/2127 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 4/752 1% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Other Sarcomas | 0/69 0% | 4/699 1% |
| Rhabdomyosarcoma | 0/33 0% | 1/171 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 8/1592 0% |
| Head and Neck Carcinoma | 1/85 1% | 7/1574 0% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 3/810 0% |
| Ovarian Carcinoma | 1/109 1% | 4/998 0% |
| Medulloblastoma | 0/0 0% | 2/450 0% |
Mutation Distribution
Where TAF6L is mutated · all tissues, split by cell line vs tissue
How many mutations in TAF6L were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 300 mutations in TAF6L
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|